Fredrik Ottosson1, Eduard Baco1, Peter M Lauritzen2, Erik Rud3. 1. Department of Urology, Oslo University Hospital, Aker, Oslo, Norway. 2. Division of Radiology and Nuclear Medicine, Oslo University Hospital, Aker, Oslo, Norway. 3. Division of Radiology and Nuclear Medicine, Oslo University Hospital, Aker, Postboks 4959, Nydalen, 0424, Oslo, Norway. erik.rud@ous.hf.no.
Abstract
OBJECTIVE: The aim of this study was to assess the prevalence and distribution of bone metastases in treatment-naïve prostate cancer patients eligible for a metastatic workup using whole-body MRI, and to evaluate the results in light of current guidelines. METHODS: This single-institution, retrospective study included all patients with treatment-naïve prostate cancer referred to whole-body MRI during 2016 and 2017. All were eligible for a metastatic workup according to the guidelines: PSA > 20 ng/ml and/or Gleason grade group ≥ 3 and/or cT ≥ 2c and/or bone symptoms. The definition of a metastasis was descriptive and based on the original MRI reports. The anatomical location of metastases was registered. RESULTS: We included 161 patients with newly diagnosed prostate cancer of which 36 (22%) were intermediate-risk and 125 (78%) were high-risk. The median age and PSA were 71 years (IQR 64-76) and 13 ng/ml (IQR 8-28), respectively. Bone metastases were found in 12 patients (7%, 95% CI: 4-13), and all were high-risk with Gleason grade group ≥ 4. The pelvis was affected in 4 patients, and the spine + pelvis in the remaining 8. No patients demonstrated metastases to the spine without concomitant metastases in the pelvis. Limitations are the small number of metastases and retrospective design. CONCLUSION: This study suggests that the overall prevalence of bone metastases using the current guidelines for screening is quite low. No metastases were seen in the case of Gleason grade group ≤ 3, and further studies should investigate if it necessary to screen non-high-risk patients. KEY POINTS: • The overall prevalence of bone metastases was 7% in the case of newly diagnosed intermediate- and high-risk prostate cancer. • The prevalence in high-risk patients was 10%, and no metastases were seen in patients with Gleason grade group ≤ 3. • The pelvic skeleton is the main site, and no metastases occurred in the spine without concomitant pelvic metastases.
OBJECTIVE: The aim of this study was to assess the prevalence and distribution of bone metastases in treatment-naïve prostate cancerpatients eligible for a metastatic workup using whole-body MRI, and to evaluate the results in light of current guidelines. METHODS: This single-institution, retrospective study included all patients with treatment-naïve prostate cancer referred to whole-body MRI during 2016 and 2017. All were eligible for a metastatic workup according to the guidelines: PSA > 20 ng/ml and/or Gleason grade group ≥ 3 and/or cT ≥ 2c and/or bone symptoms. The definition of a metastasis was descriptive and based on the original MRI reports. The anatomical location of metastases was registered. RESULTS: We included 161 patients with newly diagnosed prostate cancer of which 36 (22%) were intermediate-risk and 125 (78%) were high-risk. The median age and PSA were 71 years (IQR 64-76) and 13 ng/ml (IQR 8-28), respectively. Bone metastases were found in 12 patients (7%, 95% CI: 4-13), and all were high-risk with Gleason grade group ≥ 4. The pelvis was affected in 4 patients, and the spine + pelvis in the remaining 8. No patients demonstrated metastases to the spine without concomitant metastases in the pelvis. Limitations are the small number of metastases and retrospective design. CONCLUSION: This study suggests that the overall prevalence of bone metastases using the current guidelines for screening is quite low. No metastases were seen in the case of Gleason grade group ≤ 3, and further studies should investigate if it necessary to screen non-high-risk patients. KEY POINTS: • The overall prevalence of bone metastases was 7% in the case of newly diagnosed intermediate- and high-risk prostate cancer. • The prevalence in high-risk patients was 10%, and no metastases were seen in patients with Gleason grade group ≤ 3. • The pelvic skeleton is the main site, and no metastases occurred in the spine without concomitant pelvic metastases.
Entities:
Keywords:
Magnetic resonance imaging; Neoplasms metastases; Prostatic neoplasm; Risk assessment
Authors: Ahmed Larbi; Benjamin Dallaudière; Vasiliki Pasoglou; Anwar Padhani; Nicolas Michoux; Bruno C Vande Berg; Bertrand Tombal; Frédéric E Lecouvet Journal: Prostate Date: 2016-05-16 Impact factor: 4.104
Authors: Thabo Lengana; Ismaheel O Lawal; Tebatso G Boshomane; Gbenga O Popoola; Kgomotso M G Mokoala; Evelyn Moshokoa; Alex Maes; Neo P Mokgoro; Christophe Van de Wiele; Mariza Vorster; Mike M Sathekge Journal: Clin Genitourin Cancer Date: 2018-07-21 Impact factor: 2.872
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford Journal: Eur Urol Date: 2016-08-25 Impact factor: 20.096
Authors: Alberto Briganti; Niccolò Passoni; Matteo Ferrari; Umberto Capitanio; Nazareno Suardi; Andrea Gallina; Luigi Filippo Da Pozzo; Maria Picchio; Valerio Di Girolamo; Andrea Salonia; Liugi Gianolli; Cristina Messa; Patrizio Rigatti; Francesco Montorsi Journal: Eur Urol Date: 2009-12-18 Impact factor: 20.096
Authors: Erik Rud; Daniyal Noor; Kristina Flor Galtung; Fredrik Ottosson; Maciej Jacewicz; Eduard Baco; Peter Mæhre Lauritzen Journal: Eur Radiol Date: 2022-08-08 Impact factor: 7.034